Domabio

Executive Summary

Domabio is a Chinese biotechnology company focused on developing novel bispecific antibody-drug conjugates (ADCs) for oncology. Leveraging proprietary fully human antibody platforms from its parent company Biocytogen, Domabio aims to create first-in-class and best-in-class therapies. Operating with a dual model of internal R&D and incubation of external ventures, the company has raised approximately $130 million (CNY 950 million) since its founding in 2021 and is currently in Phase 1 clinical development. Its pipeline targets solid tumors with potentially differentiated mechanisms, including bispecific ADCs designed to improve tumor selectivity and reduce off-target toxicity. Domabio's early-stage progress is supported by a strong antibody engineering platform and a growing research team of 50-200 employees based in Suzhou. While the company has not yet disclosed detailed clinical data, upcoming milestones such as Phase 1 data readouts and potential partnership announcements could significantly influence its trajectory. The bispecific ADC space is competitive, but Domabio's access to diverse antibody libraries and its incubator model may provide strategic advantages in expanding its pipeline efficiently.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 data readout for lead bispecific ADC candidate70% success
• Q2 2026Presentation of preclinical data at major oncology conference (e.g., ASCO)80% success
• Q4 2026Partnership or licensing deal for co-development of pipeline assets60% success